Milnubes / Curiosity, with sourcesBotany · Culture · Science
milnubes.
Milnubes/Encyclopedia/CBDB
Cannabinoid atlas / Reference entry
CBDB
Plant cannabinoids

Cannabidibutol

Getting to know CBDB involves two separate questions: how to recognise its identity, and which evidence describes its effects. The distinction helps us read a composition report without turning every new name into a medical application that still requires proof.

Documentary review: Milnubes editorial desk · assisted by AI
A pink-gloved hand holds a pipette over a vessel of orange liquid.
Stock photograph providing context for this entry. It does not document a trial, participant, identified product or CBDB result.
Evidence map

Laboratory or animals. This label summarises the type of data; it is neither a recommendation to use nor a safety rating.

How we read studies and personal accounts ↗

Identity

Cannabidibutol: a CBD homologue with a four-carbon side chain, characterised in 2019 during analysis of impurities in hemp-derived CBD.

Source · Analysis of impurities of cannabidiol from hemp. Isolation, characterization and synthesis of cannabidibutol, the novel cannabidiol butyl analog

Terms associated with this entry: cannabidibutol, CBD-C4.

An impurity can also be a discovery

The supporting data describe spectroscopic characterisation and comparison with a standard. Here, “impurity” expresses a difference from the compound intended for purification; the word alone is not a toxicological classification.

Source · Chemical and spectroscopic characterization data of “cannabidibutol”, a novel cannabidiol butyl analog

What the tumour-cell study means

A 2021 study investigated CBDB in human breast-cancer cells and observed changes in viability and oxidative stress. These were cell cultures, not patients; the result does not establish a cancer treatment.

Source · Oxidative Stress and Multi-Organel Damage Induced by Two Novel Phytocannabinoids, CBDB and CBDP, in Breast Cancer Cells

The leap a news story must avoid

A cell response opens a line of research. Discussing clinical usefulness requires other questions to be answered, including whether the result is selective and whether it can be achieved with an acceptable balance of effects in the body. Adding “natural” to the compound’s name does not complete that journey.

Source · Oxidative Stress and Multi-Organel Damage Induced by Two Novel Phytocannabinoids, CBDB and CBDP, in Breast Cancer Cells

What has been studied

No established clinical benefit

Cell research does not demonstrate a cancer treatment.

Source · Oxidative Stress and Multi-Organel Damage Induced by Two Novel Phytocannabinoids, CBDB and CBDP, in Breast Cancer Cells

Risks and gaps

Experimental cytotoxicity does not define a safety balance in patients.

Source · Oxidative Stress and Multi-Organel Damage Induced by Two Novel Phytocannabinoids, CBDB and CBDP, in Breast Cancer Cells

Documented forms

Characterised sampleSpectroscopic documentation describes identity, not a therapeutic formulation.
Source · Chemical and spectroscopic characterization data of “cannabidibutol”, a novel cannabidiol butyl analog

A molecule and a product are different things. Read about flowers, resins, oils, creams, capsules and vaping.

Experiences

We have not included a verifiable individual account in this review. We do not fill that gap with commercial stories or invented experiences.

Conclusion

This profile contains both a firm chemical identification and open biological questions. Keep both in view: recognising a substance does not amount to having a medical indication for it.

Legal context

Read the Spain note and official sources. Absence from a cited list does not establish that a product is lawful.

Sources

  1. Analysis of impurities of cannabidiol from hemp. Isolation, characterization and synthesis of cannabidibutol, the novel cannabidiol butyl analog · Original research
  2. Chemical and spectroscopic characterization data of “cannabidibutol”, a novel cannabidiol butyl analog · Original research
  3. Oxidative Stress and Multi-Organel Damage Induced by Two Novel Phytocannabinoids, CBDB and CBDP, in Breast Cancer Cells · Laboratory study

Source review: 2026-11-02. No external clinical review. Corrections: info@milnubes.com.